Medasense Biometrics

Executive Summary

Medasense Biometrics is an Israeli med-tech company pioneering objective pain quantification through its AI-driven, non-invasive NOL® (Nociception Level) sensor technology. The company's flagship product, the PMD-200™ monitor, is already deployed in critical-care and intra-operative settings, providing real-time, personalized pain assessment that enables clinicians to optimize analgesic dosing and reduce opioid use. By replacing subjective pain scales with an objective physiological metric, Medasense addresses a critical unmet need in anesthesia and pain management, improving patient outcomes while mitigating the opioid crisis. The company operates in the commercial stage with a growing installed base in hospitals across Europe and Israel. Its technology is supported by a strong evidence base, with multiple clinical studies validating the NOL index's accuracy. Medasense is well-positioned to capitalize on increasing regulatory and payer emphasis on opioid stewardship and value-based care. Key growth catalysts include expanding into the U.S. market (pending FDA clearance), securing strategic partnerships with leading anesthesia equipment distributors, and developing next-generation algorithms for broader critical-care applications. With a lean team and proprietary data moat, the company offers a compelling investment opportunity in the digital health and pain management space.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) clearance for PMD-200 in the U.S. market60% success
• Q2 2026Distribution partnership with a major anesthesia equipment provider for European expansion70% success
• Q3 2026Publication of new clinical data demonstrating reduced opioid consumption in postoperative patients85% success